Takeda presents positive results for mobocertinib in patients with egfr exon20 insertion+ mnsclc who received prior platinum-based chemotherapy

Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) (“takeda”) today announced new data from the phase 1/2 trial of mobocertinib (tak-788) orally administered in previously treated patients with epidermal growth factor receptor (egfr) exon20 insertion+ metastatic non-small cell lung cancer (mnsclc) will be presented as a late-breaking oral session at the international association for the study of lung cancer (iaslc) 2020 world conference o
TAK Ratings Summary
TAK Quant Ranking